Filtered By:
Source: International Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 388 results found since Jan 2013.
Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification
We compared thromboembolic (TE) and bleeding risks in patients with atrial fibrillation (AF) according to the new ‘Evaluated Heartvalves, Rheumatic or Artificial’ (EHRA) valve classification.
Source: International Journal of Cardiology - March 7, 2018 Category: Cardiology Authors: Arnaud Bisson, Alexandre Bodin, Nicolas Clementy, Anne Bernard, Dominique Babuty, Gregory Y.H. Lip, Laurent Fauchier Source Type: research
Could the CHA2DS2-VASc schema help stratify risk of ischemic stroke for individual patients with congestive heart failure?
We read the article “Risk of stroke in congestive heart failure with and without atrial fibrillation” by Kang et al. [1] interestingly, which has great clinical significance in prevention of ischemic stroke during the management of congestive heart failure (CHF) patients. CHF has been shown to be associated with2 t o 3 times higher risk of stroke [2,3], also known as cardioembolism that is due to thrombus formation caused by atrial fibrillation (AF) or stagnation of blood in the left ventricle [4,5].
Source: International Journal of Cardiology - March 3, 2018 Category: Cardiology Authors: Jing Bai, Deliang Shen, Bo Wang, Qing Han, Peiwen Wang, Jinying Zhang Tags: Letter to the Editor Source Type: research
The CHA2DS2-VASc score: Not as simple as it seems
The CHA2DS2-VASc score has been widely adopted as a risk stratification tool for strokes in patients with atrial fibrillation and to help in deciding when anticoagulation therapy for stroke prophylaxis may be beneficial. The score as a whole has been well validated and has been included in the current major practice guidelines. An advantage of the CHA2DS2-VASc score is its ease of use, allowing clinicians to quickly estimate risk based on a short set of criteria. However, the benefit of simplicity may also be a weakness.
Source: International Journal of Cardiology - March 3, 2018 Category: Cardiology Authors: Xiaoming Jia, Glenn N. Levine, Yochai Birnbaum Source Type: research
Could direct oral anticoagulants be an alternative to vitamin K antagonists in patients with hypertrophic cardiomyopathy and atrial fibrillation?
We read the article “Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation” by Fernando Dominguez et al. [1] interestingly, which has great clinical significance in guiding the use of oral anticoagulants in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrilla tion (AF). Due to the high risk of stroke and thromboembolic complications in patients with HCM and AF, vitamin K antagonists (VKAs) are recommended for those patients, direct oral anticoagulants (NOACs) may represent another option [2].
Source: International Journal of Cardiology - February 15, 2018 Category: Cardiology Authors: Biao Li, Chao Sun, Fen Qin, Na Liu, Zhihong Wu, Qiming Liu Tags: Letter to the Editor Source Type: research
PS. It was me all along! Emergence of phosphatidylserine in the procoagulant state in atrial fibrillation
Atrial fibrillation (AF) is the most common form of arrhythmia and associated with a 5-fold increase in the risk of thromboembolic stroke. Current treatment therefore consists of anticoagulation to reduce thromboembolic events and ischemic stroke. AF fulfills Virchow's triad of hemostasis, vessel wall abnormalities and hypercoagulation, but the relationship between AF and altered hemostatic balance appears to be much more complex. The IMPACT study [1] highlighted a temporal dissociation between atrial arrhythmias and thromboembolism or ischemic events, and patients with paroxysmal and persistent AF do not consistently exhi...
Source: International Journal of Cardiology - February 12, 2018 Category: Cardiology Authors: Anke C. Fender Tags: Editorial Source Type: research
The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation
The EXPAND study examined the real-world efficacy and safety of rivaroxaban for the prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular atrial fibrillation (NVAF).
Source: International Journal of Cardiology - February 3, 2018 Category: Cardiology Authors: Hiroaki Shimokawa, Takeshi Yamashita, Shinichiro Uchiyama, Takanari Kitazono, Wataru Shimizu, Takanori Ikeda, Masahiro Kamouchi, Koichi Kaikita, Koji Fukuda, Hideki Origasa, Ichiro Sakuma, Keijiro Saku, Yasuo Okumura, Yuichiro Nakamura, Hideo Morimoto, Na Source Type: research
Optimizing bleeding risk assessment in patients with atrial fibrillation: To score or not to score?
Oral anticoagulant therapy (OAC) significantly reduces stroke and all-cause mortality in patients with atrial fibrillation (AF), but is often underused due to concerns about OAC-related bleeding [1]. Balancing the stroke and bleeding risks in AF patients sometimes may be challenging, especially in those with multiple risk factors, since AF-related stroke and OAC-related bleeding share many common risk factors, and the net clinical benefit from OAC is often even greater in high-risk patients compared with those perceived to be at low risk of bleeding [2].
Source: International Journal of Cardiology - January 29, 2018 Category: Cardiology Authors: Neboj ša Mujović, Tatjana S. Potpara Tags: Editorial Source Type: research
The impact of migration on cardiovascular diseases
Cardiovascular disease (CVD) is now the leading contributor to disability-adjusted life years lost worldwide [1]. Within CVD, ischaemic heart disease and stroke rank first and second [1], with hypertensive heart disease and heart failure, rheumatic heart disease (RHD), cardiomyopathy and atrial fibrillation also contributing substantially [2]. There is clear international commitment to address this issue. The WHO 25 ×25 Global Action Plan [3], and the Sustainable Development Goals [4] set ambitious targets to reduce premature mortality from CVD.
Source: International Journal of Cardiology - January 29, 2018 Category: Cardiology Authors: Anna Odone, Charlotte McKee, Martin McKee Tags: Editorial Source Type: research
Identification, risk assessment, and management of patients with atrial fibrillation in a large primary care cohort
Atrial fibrillation (AF) is associated with increased risk of cardiovascular disease (CVD) complications including stroke. We investigated the assessment and management of cardiovascular risk among patients with AF aged 35 –74years, by ethnic group, in a large cohort of people receiving a CVD risk assessment in primary care (PREDICT).
Source: International Journal of Cardiology - January 29, 2018 Category: Cardiology Authors: Katrina K. Poppe, Robert N. Doughty, Matire Harwood, P. Alan Barber, Jeff Harrison, Rod Jackson, Sue Wells Source Type: research
Atrial fibrillation and stroke risk factors induce decline in creatinine clearance: Is there a specific “fibrillatory kidney disease”?
Atrial fibrillation (AF) and the presence of chronic kidney disease (CKD) seem to be related. There are hints that AF has a direct impact on kidney function and expression of renal peptidases/proteases [1]. Interestingly, CKD may also interfere with atrial pathology, which may also affect atrial thrombogenesis [2]. Thus, decline of renal function appears to affect outcome in AF patients. However, the true impact of impaired kidney function has never been addressed or included in accepted AF risk scoring systems.
Source: International Journal of Cardiology - January 4, 2018 Category: Cardiology Authors: Andreas Goette Tags: Editorial Source Type: research
The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease
The decline of renal function affects stroke risk in patients with atrial fibrillation (AF). Here, we aim to study the predictive value of the CHA2DS2-VASc score, a stroke-risk stratification model in AF, for renal function and renal decline in patients with AF and chronic kidney disease (CKD).
Source: International Journal of Cardiology - January 4, 2018 Category: Cardiology Authors: Jan Beyer-Westendorf, Reinhold Kreutz, Florian Posch, Cihan Ay Source Type: research
Antiplatelet therapy, vitamin K antagonist and low time in therapeutic range in patients with atrial fibrillation: Highway to bleed
Use of oral anticoagulant (OAC) therapy for stroke prevention is a main aspect of management for patients with atrial fibrillation (AF). Guidelines for the management of AF indicate that OAC is usually needed in patients with at least one stroke risk factor [1]. This has been possibly achieved for a long time using a vitamin K antagonist (VKA). This may also be done for a few years using one of the non-vitamin K oral anticoagulant (NOACs) in case the patient has neither a EHRA (Evaluated Heartvalves, Rheumatic or Artificial) Type 1 valvular AF nor a contraindication to NOAC [2].
Source: International Journal of Cardiology - December 15, 2017 Category: Cardiology Authors: Laurent Fauchier, Arnaud Bisson, Thibaud Genet Tags: Editorial Source Type: research
Could excessive atrial ectopic activity be an independent risk factor for ischemic stroke?
We read the article “Excessive atrial ectopic activity as an independent risk factor for ischemic stroke” by Marinheiro et al. [1] interestingly, which has great significance in shedding light on the relationship between excessive atrial ectopic activity (EAEA) and ischemic stroke, atrial fibrillation (AF) and over all death. EAEA has been shown to be associated with an increased risk of AF and stroke [2–3], however, the precise definition for “excessive” atrial ectopy and the cut-off value of premature atrial contractions (PACs) were ambiguous [3–4].
Source: International Journal of Cardiology - November 30, 2017 Category: Cardiology Authors: Fen Qin, Na Liu, Chaoshuo Liu, Fan Bai, Chao Sun, Biao Li, Qiming Liu, Zhenjiang Liu Tags: Letter to the Editor Source Type: research
Should small-to-moderate alcohol consumption be recommended for healthy middle-aged women?
Sex-specific differences may exist in the association of alcohol consumption and atrial fibrillation. The article by Gallagher et al. [1] demonstrated that significant associations between moderate alcohol consumption and increased risk of atrial fibrillation among men but not among women. Low alcohol consumption is not associated with an increased risk of atrial fibrillation in both genders. Light to moderate alcohol consumption has been consistently associated with reduced risks of coronary heart disease, stroke, and congestive heart failure.
Source: International Journal of Cardiology - November 30, 2017 Category: Cardiology Authors: Yang Yang, Die Hu, Daoquan Peng Tags: Letter to the Editor Source Type: research
Percutaneous left atrial appendage closure versus oral anticoagulant: A bird in the hand is worth two in the bush?
Since the technology of percutaneous left atrial closure (LAAC) was developed to prevent thromboembolic events in non-valvular atrial fibrillation (AF) patients, debate continues over its risks and benefits. Some support LAAC as it significantly reduces bleeding and all-cause mortality and is non-inferior, if not superior, to warfarin in terms of stroke prevention [1,2]; however, others question the data retrieved from the LAAC-related trials and argue the efficacy and safety of LAAC devices. The more the device is used, the stronger the voice from both camps.
Source: International Journal of Cardiology - November 30, 2017 Category: Cardiology Authors: Rong Bai Tags: Editorial Source Type: research
